COVID-19-Associated Pulmonary Aspergillosis: A Single-Center Experience in Central Valley, California, January 2020–March 2021

Reports of coronavirus disease 2019 (COVID-19)-associated pulmonary aspergillosis (CAPA) have been widely published across the world since the onset of the pandemic with varying incidence rates. We retrospectively studied all patients with severe COVID-19 infection who were admitted to our tertiary...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Geetha Sivasubramanian, Hebah Ghanem, Michele Maison-Fomotar, Ratnali Jain, Robert Libke
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	Covid-19 invasive pulmonary aspergillosis CAPA Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/022e9c267f2a4d7a835446a59be24154
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:022e9c267f2a4d7a835446a59be24154
record_format	dspace
spelling	oai:doaj.org-article:022e9c267f2a4d7a835446a59be241542021-11-25T18:06:03ZCOVID-19-Associated Pulmonary Aspergillosis: A Single-Center Experience in Central Valley, California, January 2020–March 202110.3390/jof71109482309-608Xhttps://doaj.org/article/022e9c267f2a4d7a835446a59be241542021-11-01T00:00:00Zhttps://www.mdpi.com/2309-608X/7/11/948https://doaj.org/toc/2309-608XReports of coronavirus disease 2019 (COVID-19)-associated pulmonary aspergillosis (CAPA) have been widely published across the world since the onset of the pandemic with varying incidence rates. We retrospectively studied all patients with severe COVID-19 infection who were admitted to our tertiary care center′s intensive care units between January 2020 and March 2021, who also had respiratory cultures positive for <i>Aspergillus</i> species. Among a large cohort of 970 patients admitted to the ICU with severe COVID-19 infections during our study period, 48 patients had <i>Aspergillus</i> species growing in respiratory cultures. Based on the 2020 European Confederation of Medical Mycology and the International Society for Human and Animal Mycology (ECMM/ISHAM) consensus criteria, 2 patients in the study had proven CAPA, 9 had probable CAPA, and 37 had possible CAPA. The incidence of CAPA was 5%. The mean duration from a positive COVID-19 test to <i>Aspergillus</i> spp. being recovered from the respiratory cultures was 16 days, and more than half of the patients had preceding fever or worsening respiratory failure despite adequate support and management. Antifungals were given for treatment in 44% of the patients for a mean duration of 13 days. The overall mortality rate in our study population was extremely high with death occurring in 40/48 patients (83%).Geetha SivasubramanianHebah GhanemMichele Maison-FomotarRatnali JainRobert LibkeMDPI AGarticleCovid-19invasive pulmonary aspergillosisCAPABiology (General)QH301-705.5ENJournal of Fungi, Vol 7, Iss 948, p 948 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Covid-19 invasive pulmonary aspergillosis CAPA Biology (General) QH301-705.5
spellingShingle	Covid-19 invasive pulmonary aspergillosis CAPA Biology (General) QH301-705.5 Geetha Sivasubramanian Hebah Ghanem Michele Maison-Fomotar Ratnali Jain Robert Libke COVID-19-Associated Pulmonary Aspergillosis: A Single-Center Experience in Central Valley, California, January 2020–March 2021
description	Reports of coronavirus disease 2019 (COVID-19)-associated pulmonary aspergillosis (CAPA) have been widely published across the world since the onset of the pandemic with varying incidence rates. We retrospectively studied all patients with severe COVID-19 infection who were admitted to our tertiary care center′s intensive care units between January 2020 and March 2021, who also had respiratory cultures positive for <i>Aspergillus</i> species. Among a large cohort of 970 patients admitted to the ICU with severe COVID-19 infections during our study period, 48 patients had <i>Aspergillus</i> species growing in respiratory cultures. Based on the 2020 European Confederation of Medical Mycology and the International Society for Human and Animal Mycology (ECMM/ISHAM) consensus criteria, 2 patients in the study had proven CAPA, 9 had probable CAPA, and 37 had possible CAPA. The incidence of CAPA was 5%. The mean duration from a positive COVID-19 test to <i>Aspergillus</i> spp. being recovered from the respiratory cultures was 16 days, and more than half of the patients had preceding fever or worsening respiratory failure despite adequate support and management. Antifungals were given for treatment in 44% of the patients for a mean duration of 13 days. The overall mortality rate in our study population was extremely high with death occurring in 40/48 patients (83%).
format	article
author	Geetha Sivasubramanian Hebah Ghanem Michele Maison-Fomotar Ratnali Jain Robert Libke
author_facet	Geetha Sivasubramanian Hebah Ghanem Michele Maison-Fomotar Ratnali Jain Robert Libke
author_sort	Geetha Sivasubramanian
title	COVID-19-Associated Pulmonary Aspergillosis: A Single-Center Experience in Central Valley, California, January 2020–March 2021
title_short	COVID-19-Associated Pulmonary Aspergillosis: A Single-Center Experience in Central Valley, California, January 2020–March 2021
title_full	COVID-19-Associated Pulmonary Aspergillosis: A Single-Center Experience in Central Valley, California, January 2020–March 2021
title_fullStr	COVID-19-Associated Pulmonary Aspergillosis: A Single-Center Experience in Central Valley, California, January 2020–March 2021
title_full_unstemmed	COVID-19-Associated Pulmonary Aspergillosis: A Single-Center Experience in Central Valley, California, January 2020–March 2021
title_sort	covid-19-associated pulmonary aspergillosis: a single-center experience in central valley, california, january 2020–march 2021
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/022e9c267f2a4d7a835446a59be24154
work_keys_str_mv	AT geethasivasubramanian covid19associatedpulmonaryaspergillosisasinglecenterexperienceincentralvalleycaliforniajanuary2020march2021 AT hebahghanem covid19associatedpulmonaryaspergillosisasinglecenterexperienceincentralvalleycaliforniajanuary2020march2021 AT michelemaisonfomotar covid19associatedpulmonaryaspergillosisasinglecenterexperienceincentralvalleycaliforniajanuary2020march2021 AT ratnalijain covid19associatedpulmonaryaspergillosisasinglecenterexperienceincentralvalleycaliforniajanuary2020march2021 AT robertlibke covid19associatedpulmonaryaspergillosisasinglecenterexperienceincentralvalleycaliforniajanuary2020march2021
_version_	1718411600030859264

COVID-19-Associated Pulmonary Aspergillosis: A Single-Center Experience in Central Valley, California, January 2020–March 2021

Ejemplares similares